Trial Profile

A Multicenter, Open-Label, Randomized Study to Assess the Metabolics, Efficacy, and Safety of Once-Daily Darunavir Versus Atazanavir in HIV-Infected Treatment-Naive Adult Patients.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atazanavir (Primary) ; Darunavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
Indications HIV-1 infections
Focus Adverse reactions; Pharmacodynamics
Acronyms METABOLIK
Sponsors Tibotec Inc

Most Recent Events

26 Feb 2016 Results of substudy published in the HIV Clinical Trials
13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
17 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com